Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | HTR1D | P28221 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR1B | P28222 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053035 | 1.00 | IDO1 (0.51) | IDO1HTR1DHTR2AHTR1BL3MBTL1 | |
| SCHEMBL11637272 | 0.85 | GPR84 (0.55) | IDO1HTR2AMTNR1AMTNR1BGSK3B | |
| SCHEMBL11764111 | 0.84 | NPSR1 (0.51) | IDO1HTR1DHTR2AHTR1BGSK3B | |
| SCHEMBL11634227 | 0.84 | GPR84 (0.57) | HTR1DHTR2AHTR1BL3MBTL1MTNR1A | |
| SCHEMBL28884409 | 0.81 | IDO1 (0.75) | IDO1L3MBTL1GSK3BLMNAMEN1 | |
| SCHEMBL838519 | 0.81 | IDO1 (0.75) | IDO1L3MBTL1GSK3BLMNAMEN1 | |
| Potassium SCHEMBL837807 | 0.80 | IDO1 (0.73) | IDO1L3MBTL1GSK3BLMNAMEN1 | |
| SCHEMBL837806 | 0.80 | IDO1 (0.73) | IDO1L3MBTL1GSK3BLMNAMEN1 | |
| SCHEMBL17828341 | 0.78 | RIPK1 (0.56) | IDO1HTR1DHTR2AHTR1BL3MBTL1 | |
| SCHEMBL29764778 | 0.76 | IDO1 (0.51) | IDO1L3MBTL1GSK3BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-01-24 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-9499521-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499521-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | IDO1 1237/4885HTR1D 4626/4885HTR2A 4383/4885 |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | IDO1 1237/4885HTR1D 4626/4885HTR2A 4383/4885 |
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | IDO1 1237/4885HTR1D 4626/4885HTR2A 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.